Menu
MorphoSys US

Our mission is to make exceptional, innovative biopharmaceuticals to improve the lives of patients suffering from serious diseases.

Taking Big Steps

Visit our Online Magazine

MorphoSys' mission

MorphoSys mission is to make exceptional, innovative biopharmaceuticals to improve the lives of patients suffering from serious diseases. Our focus is on cancer. Innovative technologies and smart development strategies are central to our approach.

Latest
news

12/01/2021
MorphoSys and Incyte Announce Acceptance by Health Canada of the New Drug...
Read Media Release
11/01/2021
MorphoSys To Present At the 39th Annual J.P. Morgan Healthcare Conference
Read Media Release
06/01/2021
MorphoSys Appoints Sung Lee as Chief Financial Officer
Read Media Release
05/01/2021
MorphoSys and Incyte Announce the Acceptance of the Swissmedic Marketing...
Read Media Release
17/12/2020
MorphoSys AG: Corporate Calendar 2021
Read Media Release
07/12/2020
Data Evaluating Tafasitamab with and without Lenalidomide in Combination...
Read Media Release
02/12/2020
MorphoSys' Licensee Announces Approval by the European Commission for...
Read Media Release
01/12/2020
Thomas Biegi Joins MorphoSys as Head of Corporate Communications
Read Media Release
11/11/2020
MorphoSys Reports Nine Months and Third Quarter 2020 Results
Read Media Release
11/11/2020
MorphoSys and Cherry Biolabs Announce licensing of Hemibody Technology
Read Media Release

January 13, 2021
Webcast
J.P. Morgan Healthcare Conference

Full details

You are leaving morphosys.com and will be transferred to the MorphoSys US website which is intended for US residents.

Do you wish to proceed?

Yes No